research use only
Cat.No.S2373
|
In vitro |
DMSO
: 16 mg/mL
(40.93 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 390.9 | Formula | C21H26N2O3.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 65-19-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Antagonil | Smiles | COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl | ||
| Targets/IC50/Ki |
alpha 2-adrenergic receptor
|
|---|---|
| In vitro |
Yohimbine(Antagonil) has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. Yohimbine is a pre-synaptic alpha 2-adrenergic blocking agent. Yohimbine may exert its beneficial effect on erectile ability through blockade of central alpha 2-adrenergic receptors producing an increase in sympathetic drive secondary to an increase in norepinephrine release and in firing rate of cells in the brain noradrenergic nuclei.
|
| In vivo |
LD50: Mice 55mg/kg (i.p.)
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04346394 | Withdrawn | Parkinson Disease |
Nathaniel M. Robbins|Dartmouth-Hitchcock Medical Center |
May 11 2021 | Early Phase 1 |
| NCT04051619 | Completed | Opioid Use Disorder |
Brown University |
January 6 2020 | Phase 1 |
| NCT00605904 | Completed | Alcoholism |
National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC) |
January 2008 | Phase 2 |
| NCT00000196 | Withdrawn | Opioid-Related Disorders |
Yale University|National Institute on Drug Abuse (NIDA) |
January 1993 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.